Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Supply readiness follows months of manufacturing to ensure timely and ample supply
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
Subscribe To Our Newsletter & Stay Updated
